Dalrada Technology Group entered into a settlement agreement with IBS Equity Fund III and IBS Private Credit Fund IV to resolve a dispute over alleged defaults and $1.16 million in demanded fees. The company paid a $20,000 lump-sum settlement to terminate all prior financing documents, cancel a secured promissory note and pre-funded warrant, and release all liens and guarantees.
Counterparty
IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC
Dalrada Technology Group Deal Termination with IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC
Dalrada Technology Group's subsidiary, Genefic, Inc., has terminated its financing relationship with IBS Equity Fund III and IBS Private Credit Fund IV, which included a $20 million standby letter of credit facility and a $5 million credit facility. Although no funding was ever received under these agreements, IBS has asserted events of default and is demanding early termination fees and the acceleration of obligations, which the company disputes.
Counterparty
IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC